US pushes security ally Australia to spend more on defence
By Kirsty Needham
SYDNEY (Reuters) -U.S. Defence Secretary Pete Hegseth has asked security ally Australia to increase defence spending in a meeting with Defence Minister Richard Marles on Friday in Singapore.
The defence chiefs also discussed the need to significantly lift U.S. submarine production rates to meet AUKUS targets.
Australia is scheduled to pay the United States $2 billion by the end of 2025 to assist its submarine shipyards, in order to buy three Virginia-class submarines starting in 2032 -- its biggest ever defence project.
The defence ministers meeting on the sidelines of the Shangri-La Dialogue, Asia's premier security forum, is only the second between the security allies since the Trump Administration took office.
Hegseth had "respectfully" said Australia should increase defence spending, Marles said in an Australian Broadcasting Corporation television interview after the meeting.
"Clearly we have increased defence spending significantly and that is acknowledged, but we want to be making sure we are calibrating our defence spending to the strategic moment that we need to meet," he said.
"We are very much up for the conversation, and the American position has been clear," he added.
Marles said they did not discuss a number, although a Pentagon official had previously said Australia should spend 3% of gross domestic product.
Australia's Prime Minister Anthony Albanese, who was re-elected this month and is yet to meet U.S. President Donald Trump, did not raise defence spending in this year's national budget, saying his government had already announced a A$50 billion boost over a decade. Albanese said on Thursday defence spending would rise to 2.4%.
"In a rational world defence spending is a function of strategic threat - there is definitely strategic threat in the world today and we are rational people," Marles said.
The AUKUS submarine partnership and working together to provide stability in the Indo-Pacific were also discussed, Marles said.
"AUKUS is happening and we talked about the need to maintain the momentum," he said. "We want to be seeing a significant increase in the production and sustainment rate, the availability of Virginia class submarines for the United States fleet."
U.S. production of Virginia class attack submarines has fallen behind U.S. Navy targets, and concern has been raised in Washington over selling used submarines to Australia under AUKUS if this reduces the fleet size.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Qudian First Quarter 2025 Earnings: EPS: CN¥0.90 (vs CN¥0.38 loss in 1Q 2024)
Revenue: CN¥25.8m (down 54% from 1Q 2024). Net income: CN¥150.1m (up from CN¥73.6m loss in 1Q 2024). EPS: CN¥0.90 (up from CN¥0.38 loss in 1Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Qudian shares are up 4.6% from a week ago. What about risks? Every company has them, and we've spotted 1 warning sign for Qudian you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
25 minutes ago
- Yahoo
Nordic American Tankers First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Revenue: US$37.9m (down 37% from 1Q 2024). Net income: US$4.25m (down 72% from 1Q 2024). Profit margin: 11% (down from 25% in 1Q 2024). EPS: US$0.02 (down from US$0.072 in 1Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 13%. Earnings per share (EPS) exceeded analyst estimates. Looking ahead, revenue is expected to decline by 12% p.a. on average during the next 3 years, while revenues in the Oil and Gas industry in the US are expected to grow by 3.6%. Performance of the American Oil and Gas industry. The company's share price is broadly unchanged from a week ago. Be aware that Nordic American Tankers is showing 4 warning signs in our investment analysis and 1 of those doesn't sit too well with us... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
34 minutes ago
- Yahoo
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to results of a large trial presented on Saturday. The data is likely to change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert said. After a median follow-up of 14 months, patients treated with Trodelvy, a so-called antibody-drug conjugate, and Keytruda went 11.2 months without their cancer progressing, a measure known as progress-free survival. That compared with PFS of 7.8 months for those given the standard treatment of chemotherapy and Keytruda, researchers said. Patients given the Trodelvy/Keytruda combination responded to the treatment for a median of 16.5 months, compared with 9.2 months for the chemo group, according to full results of the study presented at the American Society of Clinical Oncology scientific meeting in Chicago. The researchers said patients are still being followed to see if the regimen has an impact on overall survival. Gilead previously said the Phase 3 study in 443 patients with advanced triple-negative breast cancer whose tumors express PD-L1 - the protein targeted by drugs like Keytruda - had met its goal. The findings suggest that the combination of Trodelvy and Keytruda "will likely become a new front-line standard of care in this setting,' Dr. Jane Lowe Meisel, co-director of breast oncology at Emory University School of Medicine and a designated ASCO expert said in a statement. ASCO estimates that about 10% of breast cancers in the United States are triple-negative. That tends to be more difficult to treat than hormone-sensitive subtypes, because it does not have the common biomarkers used to guide treatment, the tumors are often larger, and the recurrence rate is high. The medical group said that about 40% of triple-negative breast cancers are also PD-L1 positive, making them candidates for Keytruda. Antibody-drug conjugates like Trodelvy are designed to deliver an anti-cancer drug more precisely to malignant cells, causing less damage to healthy cells than chemotherapy. Serious side effects for Trodelvy included neutropenia, a condition caused by cancer treatments that lower levels of infection-fighting white blood cells, reported in 43% of patients, and diarrhea in 10%. In the chemotherapy group, the incidence of neutropenia was 45%, while 16% of patients had anemia and 14% had low blood platelet counts. Trodelvy is already approved for patients with advanced triple-negative breast cancer who had two or more prior therapies, and for previously treated hormone-receptor-positive, HER2-negative metastatic breast cancer. Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1. (Reporting By Deena BeasleyEditing by Bill Berkrot)